Side-by-side comparison of AI visibility scores, market position, and capabilities
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Alphabet Class C (no-vote shares); same $350B FY2024 revenue as GOOGL; Gemini AI across Search/Cloud/YouTube; DOJ antitrust ruling 2024; Waymo 150K+ weekly robotaxi rides.
Alphabet Inc. Class C shares (Nasdaq: GOOG) represent the same underlying business as Class A (GOOGL) but carry no shareholder voting rights—created in the 2014 stock split to allow founders Larry Page and Sergey Brin to retain control while monetizing their stakes. Alphabet is the parent company of Google, YouTube, Waymo, DeepMind, Google Cloud, and Other Bets, generating $350.0 billion in total revenues for FY2024—a 14% increase year-over-year—driven by Search advertising, YouTube, and Google Cloud Platform. CEO Sundar Pichai oversees the company's comprehensive integration of artificial intelligence across every product surface, anchored by the Gemini family of multimodal foundation models released in 2023 and continuously upgraded through 2024-2025.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.